ImmunityBio (IBRX) Expected to Announce Earnings on Tuesday

Key Points

• ImmunityBio is set to release its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($0.10) per share and revenue of $21.95 million.
• The company's stock is currently trading at $2.39, with a market capitalization of $2.11 billion and a significant price-to-earnings ratio of -4.11.
• Several analysts have reaffirmed a "buy" rating for ImmunityBio, with price targets ranging from $5.00 to $30.00, indicating a generally optimistic outlook on the stock's performance.

ImmunityBio (NASDAQ:IBRX - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $21.95 million for the quarter.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The firm had revenue of $26.43 million during the quarter, compared to analyst estimates of $21.95 million. On average, analysts expect ImmunityBio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ImmunityBio Stock Performance

IBRX traded up $0.04 during trading on Friday, hitting $2.44. The stock had a trading volume of 4,743,169 shares, compared to its average volume of 7,679,560. The company has a market capitalization of $2.31 billion, a PE ratio of -5.08 and a beta of 0.12. ImmunityBio has a twelve month low of $1.83 and a twelve month high of $7.48. The stock has a 50 day simple moving average of $2.78 and a two-hundred day simple moving average of $2.83.

Institutional Investors Weigh In On ImmunityBio

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers lifted its stake in shares of ImmunityBio by 56.9% during the second quarter. Cetera Investment Advisers now owns 18,551 shares of the company's stock worth $49,000 after buying an additional 6,731 shares during the period. AQR Capital Management LLC lifted its position in ImmunityBio by 193.4% during the first quarter. AQR Capital Management LLC now owns 44,448 shares of the company's stock valued at $134,000 after purchasing an additional 29,297 shares during the period. Finally, Creative Planning lifted its position in ImmunityBio by 9.2% during the second quarter. Creative Planning now owns 62,028 shares of the company's stock valued at $164,000 after purchasing an additional 5,231 shares during the period. 8.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on IBRX shares. Piper Sandler upgraded shares of ImmunityBio from a "neutral" rating to an "overweight" rating and raised their target price for the company from $4.25 to $5.00 in a research note on Tuesday, May 20th. D. Boral Capital restated a "buy" rating and issued a $30.00 target price on shares of ImmunityBio in a research note on Tuesday. Finally, HC Wainwright reiterated a "buy" rating and set a $8.00 price objective on shares of ImmunityBio in a research note on Wednesday, June 4th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $12.25.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.